Although plasmacytoid dendritic cells (pDCs) respond to virus replication in a nonspecific way by producing large amounts of type I interferon, a rapid, direct function for pDCs in activating antiviral lymphocytes is less apparent. Here we show that pDCs were able to rapidly initiate antigen-specific antiviral CD8 + T cell responses. After being exposed to virus, pDCs efficiently and rapidly internalized exogenous viral antigens and then presented those antigens on major histocompatibility complex (MHC) class I to CD8 + T cells. Processing of exogenous antigen occurred in endocytic organelles and did not require transit of antigen to the cytosol. Intracellular stores of MHC class I partially localized together with the transferrin receptor and internalized transferrin in endosomes, which suggested that such recycling endosomes are sites for loading peptide onto MHC class I or for peptide transit. Our data demonstrate that pDCs use 'ready-made' stores of MHC class I to rapidly present exogenous antigen to CD8 + T cells.
Although plasmacytoid dendritic cells (pDCs) respond to virus replication in a nonspecific way by producing large amounts of type I interferon, a rapid, direct function for pDCs in activating antiviral lymphocytes is less apparent. Here we show that pDCs were able to rapidly initiate antigen-specific antiviral CD8 + T cell responses. After being exposed to virus, pDCs efficiently and rapidly internalized exogenous viral antigens and then presented those antigens on major histocompatibility complex (MHC) class I to CD8 + T cells. Processing of exogenous antigen occurred in endocytic organelles and did not require transit of antigen to the cytosol. Intracellular stores of MHC class I partially localized together with the transferrin receptor and internalized transferrin in endosomes, which suggested that such recycling endosomes are sites for loading peptide onto MHC class I or for peptide transit. Our data demonstrate that pDCs use 'ready-made' stores of MHC class I to rapidly present exogenous antigen to CD8 + T cells.
The high rate of viral replication represents a considerable challenge for the immune response. Human dendritic cells (DCs) can be classified into two main subsets, myeloid DCs (mDCs) and plasmacytoid DCs (pDCs), both of which are critical for the initiation of viral immune responses 1, 2 . The presentation of viral peptides to CD4 + and CD8 + T cells is mediated by major histocompatibility complex (MHC) class II molecules and MHC class I molecules, respectively. DC maturation leads to a variety of changes, including activationinduced antigen processing and increased surface expression of MHC class I and MHC class II (refs. 3,4) . Exogenous antigen presentation on MHC class II molecules by mDCs is a rapid and coordinated process 5 . Pools of presynthesized MHC class II molecules are stored in late endosomal and lysosomal compartments, which are loaded in an activation-dependent way and translocated to the cell surface [6] [7] [8] [9] [10] .
In addition to MHC class I presentation of endogenous viral antigens after direct infection of DCs, mDCs are also able to present exogenous antigens bound to MHC class I molecules 11, 12 . This process, known as 'cross-presentation' , is essential to the initiation of antiviral immunity, because DCs may not be directly targeted by all viruses, or an infecting virus may compromise DC function. The underlying mechanisms of cross-presentation remain an area of active investigation. Three main models have been proposed. The first is an indirect pathway of transferring exogenous antigen from phagoendosomes to the cytosol for proteosomal processing and loading in the endoplasmic reticulum by the classical MHC class I 'machinery' 13 . The second is a direct pathway whereby antigen is processed and loaded onto MHC class I entirely in the endosomal compartment in a proteasome-independent way 14 . The third proposed model involves the delivery of components of the endoplasmic reticulum to endocytic organelles or the transport of incoming antigen to the endoplasmic reticulum 15, 16 , although the quantitative importance of this pathway remains unclear 17 .
The pDCs are a specialized subset of DCs central to the initiation of antiviral immunity, mainly through the secretion of type I interferon 18, 19 . In addition to inhibiting viral replication, type I interferons activate the antiviral function of B cells, T cells, natural killer cells and mDCs 20 . Thus, pDCs represent a critical connection between the innate and adaptive immune systems. Depletion of pDCs during viral infection leads to impaired induction of cytotoxic T lymphocytes and viral clearance 21, 22 . The ability of pDCs to act as antigen-presenting cells to directly stimulate T cell proliferation in response to viral infection, however, is less clear. Studies of mouse and human pDCs have resulted in no clear consensus, with some demonstrating little or no T cell-stimulatory ability 23 or a capacity equal to that of mDCs 24 and still others demonstrating an inhibitory function through the generation of regulatory T cells, depending on the time after activation that pDC function is assessed [25] [26] [27] .
RESULTS

CD8 + T cell proliferation driven by pDCs
We purified healthy donor pDCs and mDCs from blood by negative depletion followed by direct cell sorting for mDCs (HLA-DR hi CD11c hi ) and pDCs (HLA-DR hi CD123 hi ). We assessed their antigen-presenting function on the basis of their ability to induce the proliferation of allogeneic CD4 + and CD8 + T cells. The pDCs demonstrated no allostimulatory effect on either CD4 + or CD8 + T cells, whereas mDCs showed low stimulatory capacity (data not shown). After being activated with influenza virus, both pDCs and mDCs induced strong proliferation of allogeneic CD4 + and CD8 + T cells. Influenza virus-treated pDCs induced stronger 'alloproliferation' of CD8 + T cells than did their myeloid counterpart (Fig. 1a,b,  top) . Reactivation of the pDC-expanded CD8 + T cell populations with antibody to CD3 (anti-CD3) and anti-CD28 led to substantial secretion of interferon-g (IFN-g), which indicated the acquisition of effector function (data not shown). In contrast, influenza virustreated mDCs induced more proliferation of allogeneic CD4 + T cells (Fig. 1a,b, bottom) , which indicated that the difference in CD8 + T cell proliferation was not merely due to a maturation defect. We obtained similar results with a second, unrelated RNA virus (respiratory syncytial virus; data not shown).
Rapid cross-presentation of viral antigens by pDCs
We next analyzed the ability of pDCs and mDCs to induce autologous virus antigen-specific population expansion of CD8 + T cells from HLA-A201 + donors. In the absence of viral exposure, we found no autologous CD8 + T cell proliferation with either pDCs or mDCs (data not shown). After 18 h of exposure to influenza virus, both DC subsets were able to induce population expansion of CD8 + T cells (Fig. 2a, top) . The pDCs were more efficient in inducing such expansion in response to influenza virus. The population expansion of antigen-specific, influenza matrix protein tetramer-positive CD8 + T cells was also greater with pDCs (Fig. 2a) . A 4-hour pulse with virus was sufficient for pDCs to induce the proliferation of influenza virus-specific CD8 + T cells (Fig. 2a, bottom) . We found that pDCs were more effective than were mDCs in inducing CD8 + T cell proliferation at this early time point. To exclude the possibility that influenza virus could be continuously processed and presented during the coculture, we fixed pDCs and mDCs after a 6-hour pulse with influenza virus; fixed pDCs retained the ability to induce influenza matrix protein-specific CD8 + T cell proliferation (Fig. 2b, bottom left) . In contrast, fixed mDCs were unable to stimulate either overall or matrix protein-specific CD8 + T cell proliferation (Fig. 2b, bottom right) . In addition, pDCs exposed to influenza virus were able to prime allogeneic sorted naive CD8 + T cells, although this priming effect was considerably less potent than that of donor-matched mDCs, which indicated that rapid pDC cross-presentation leads mainly to the activation of memory CD8 + T cells ( Supplementary Fig. 1a,b online) . The population expansion of matrix protein tetramer-positive cells was specific, as we found no expansion with the control human immunodeficiency virus groupassociated antigen tetramer, and the ubiquitous activation of total CD8 + T cells with microbeads coated with anti-CD3 and anti-CD28 did not result in enrichment of matrix protein tetramer-positive cells ( Supplementary Fig. 2a,b online) . Furthermore, sorted CD8 + matrix protein tetramer-positive T cells from pDC cultures specifically recognized matrix protein-MHC class I peptide complex presented on HLA-A201 + monocyte-derived DCs ( Supplementary Fig. 2c ). As expected, pDCs did not produce type I interferon after fixation ( Supplementary Fig. 3 online) , which precluded the possibility of involvement of these molecules in directly influencing CD8 + T cell population expansion. These data demonstrate that pDCs are able to cross-present viral antigen within 6 h. Thus, pDCs are able to rapidly elicit virus-specific CD8 + T cell responses.
Influenza induces surface expression of MHC class I stores
The rapidity of the CD8 + T cell response suggested that presentation of viral antigens by pDCs may not require the synthesis of new MHC class I molecules but instead may require the loading of peptides onto a previously synthesized, intracellular pool. For mDCs, it is well known that rapid presentation of exogenous antigens involves the loading of peptides onto MHC class II molecules found in late endosomes and lysosomes 6 . We next used confocal microscopy to determine if pDCs had an analogous intracellular pool of MHC class I. Although pDCs had variable amounts of surface MHC class I, all immature pDCs had large perinuclear stores of intracellular MHC class I (Fig. 3a) . Intracellular stores were specific to pDCs, as donor-matched immature mDCs had less MHC class I expression (Fig. 3a) . Both pDCs and mDCs had intracellular stores of MHC class II, with immature pDCs having more on the plasma membrane (Fig. 3a, bottom) .
We next determined if pDC activation by influenza virus induced a redistribution of internal MHC class I to the cell surface. Exposure to the virus increased the surface expression of MHC class I (Fig. 3b) . We noted a significant increase after only 30 min (P ¼ 0.009), and it continued for at least 4 h (Fig. 3c,d and Supplementary Fig. 4 online). This rapid redistribution was specific for pDCs, as donormatched mDCs showed no increase in surface MHC class I at this early time point ( Supplementary Fig. 4a,b) . Pretreatment of pDCs with the protein synthesis inhibitor cycloheximide did not affect the increase in cell surface MHC class I on pDCs induced by 30 min of exposure to influenza virus (Fig. 3e) . Similarly, brefeldin A (which blocks endoplasmic reticulum-to-Golgi transport) also failed to inhibit the increase in surface MHC class I (Fig. 3e) . The modest but rapid increase in MHC class I at the surface, combined with its insensitivity to cycloheximide and brefeldin A, suggests that activation of immature pDCs by virus causes at least a partial redistribution of MHC class I from intracellular sites to the plasma membrane.
Storage of MHC class I in recycling endosomes in pDCs
We next sought to determine the identity of the compartments containing MHC class I. Although peptides are most typically loaded onto MHC class I molecules in the endoplasmic reticulum, the internal MHC class I in pDCs did not localize together with the following markers of the secretory pathway: calnexin (endoplasmic reticulum compartment), ERGIC-53 and COPII (endoplasmic reticulum-Golgi intermediate compartment) or GM130 (cisternal Golgi complex; molecules in late endosomal-lysosomal compartments where antigenic peptides are thought to be loaded onto MHC class II molecules 28 . MHC class I has been reported in this compartment in a subset of mDCs 29, 30 . In immature pDCs, however, MHC class I did not localize together with the late endosomal or lysosomal markers LAMP-1 and MHC class II (Fig. 4b) .
The intracellular MHC class I, however, did seem to reside in some endocytic compartment. When we allowed immature pDCs to internalize influenza virus for 45 min, we found intracellular virus in the MHC class I-containing vesicles (Fig. 4c) . Because early or recycling endosomes have been linked to signaling by Toll-like receptors 7 and 9, specific for viral nucleic acids, we determined if the MHC class I was located in the recycling endosomal compartment 31 . Indeed, in immature pDCs, intracellular MHC class I, but not MHC class II, had a distribution similar to that of the recycling endosomal marker transferrin receptor (CD71 (A000581); Fig. 4d) . Furthermore, internalized transferrin also accumulated in MHC class I-positive vesicles ( Supplementary Fig. 5 online) . This localization of MHC class I in the recycling endosomal compartment in pDCs suggests a mechanism by which MHC class I molecules may access exogenous antigen and rapidly translocate to the cell surface after viral stimulation. Furthermore, these findings are consistent with published data that recycling MHC class I molecules may be important in antigen cross-presentation in mice 32 .
Cross-presentation is independent of cytosolic transit Cross-presentation of exogenous antigen in mDCs has been described as proteasome dependent 13 . To investigate the function of proteasome processing in pDCs MHC class I peptide formation, we pretreated cells with specific inhibitors of proteolytic processing or endosomal trafficking, followed by 6 h of exposure to influenza virus (Fig. 5) . After cells were activated, we assessed cell viability and fixed the cells, washed them and incubated then with autologous CD8 + T cells.
Pretreatment of pDCs with the proteasome inhibitor lactacystin did not prevent the presentation of influenza virus-derived antigen (Fig. 5a) , in contrast to the substantial inhibition obtained with chloroquine, an acidophilic weak base that inhibits endosomal acidification (Fig. 5b) . Thus, the rapid generation of peptide MHC class I complex was independent of proteasomes and was dependent on endosomal acidification. Furthermore, the formation of MHC class I peptide complex was sensitive to the cathepsin inhibitor z-FA-fmk, which supported the idea that endosomal processing is involved in complex formation (Fig. 5c) . These results indicate that cross-presentation in pDCs is direct and does not require a cytosolic intermediate step. To determine whether the intracellular stores of MHC class I located in the recycling endosomal compartment corresponded to the population of MHC class I presenting viral peptides, we pretreated pDCs with brefeldin A to inhibit the transport of newly synthesized MHC class I. Presentation of the matrix protein peptide complex was insensitive to pretreatment with brefeldin A, which indicated that the processing noted in pDCs occurred in a postGolgi compartment and did not require the contribution of newly synthesized MHC class I for the formation of surface peptide complexes (Fig. 5d) . The formation of MHC class I peptide complex was sensitive to pretreatment with the recycling endosomal inhibitor primaquine 33 , however, which suggested involvement of MHC class I located in the recycling endosomal compartment in pDC crosspresentation (Fig. 5e ). An endosomal model of vesicular loading was further supported by the observation that pDCs were able to drive the population expansion of CD8 + T cells after uptake of inactivated virus ( Supplementary Fig. 6 online) . We further confirmed those results by assessing cytokine (IFN-g) production by a matrix protein-specific CD8 + T cell line (Fig. 5f) . Pretreatment of influenza virus-treated pDCs with chloroquine completely inhibited IFN-g production by the matrix protein-specific CD8 + T cell line, whereas pretreatment with brefeldin A had no effect (Fig. 5f) . The intravesicular nature of processing and localization in the recycling endosomal compartment ( Supplementary Fig. 7 online) could provide a mechanism for the rapid initiation of virus peptide-specific CD8 + T cell population expansion (Fig. 2) , because optimal cross-presentation through the cytosolic pathway in mDCs can take up to 18-24 h (ref. 34) .
DISCUSSION
Viral infections are characterized by rates of replication exceeding 1 Â 10 12 virions per day (ref. 35) . It is imperative that the immune system responds rapidly and specifically to this challenge. In humans, circulating pDCs are poor antigen-presenting cells that are unable to induce either CD4 + or CD8 + T cell responses and, unlike mDCs, they have no phagocytic ability 36 . However, after being activated by virus, pDCs undergo a radical transformation in both appearance and function, typified by the considerable production of type I interferons 37, 38 . Here we have shown that immediately after viral activation, pDCs, but not mDCs, were highly efficient at cross-presentation of viral peptides on MHC class I. Internalized virions or viral antigens are delivered to recycling endosomal compartments, which contain presynthesized MHC class I molecules. MHC class I loading may occur in this compartment or in another endocytic compartment, with the complexes accumulating in recycling endosomes before reaching the surface, as is true for a variety of recycling receptors. In any event, it seems unlikely that transport of viral antigens to the cytosol is required, as pDCs were able to present inactivated virus and antigen presentation was independent of proteasome function. Within minutes of viral activation, MHC class I begins to translocate to the surface of the pDC, which suggests that this pathway explains the rapidity and efficiency of pDC cross-presentation to CD8 + T cells. The description of functional Toll-like receptors present in these pDC endosomes suggests that these vesicles represent a self-contained specialized compartment for viral recognition, processing and cross-presentation 31, 39 . These findings not only demonstrate the central function of pDCs in the adaptive arm of viral immunity but also provide insight into the basic mechanisms of cross-presentation. It has been reported that pDCs are able to efficiently cross-present lipopeptides as well as human immunodeficiency antigens from apoptotic cells 40 . That study did not identify the MHC class I-rich compartment and, unlike our work here, claimed that mDCs and pDCs may use the same pathway for cross-presentation 40 . Those distinctions may reflect differences in the kinetics of MHC class I presentation investigated and mechanisms of antigen delivery. Unlike the authors of the previous study 40 , here we investigated cross-presentation that occurs almost immediately after virus entry; thus, we have demonstrated a unique feature of pDCs: the presence of a MHC class I-rich compartment that rapidly translocates to the cell surface after activation. It is the rate of generating these peptide MHC complexes that, in addition to the concurrent production of type I interferon, may be key in limiting viral replication. Early pDC cross-presentation may lead to rapid activation of peripheral antiviral memory CD8 + T cell surveillance mechanisms. Later, cross-presentation of infected cell bodies and viral debris by both pDCs and mDCs may be critical in both expanding the existing antiviral T cell population and priming new responses 12, 40 . However, this kinetically distinct cross-presentation event probably takes place after migration from the site of infection to the draining lymph node and has little consequence on the initial expansion of the virus population at the site of infection 41 .
The pDCs have four notable features to counteract viral infection: a shape similar to that of lymphocytes, for efficient trafficking to peripheral sites; an extensive endoplasmic reticulum compartment, to permit the prompt secretion of soluble factors, including type I interferons; an early endosomal compartment containing MHC class I molecules (the focus of our report here) that seems to permit direct vesicular MHC class I loading for immediate activation of memory The pDCs and mDCs were isolated based on their lack of lineage markers and high expression of HLA-DR, and CD11c (corresponding to mDCs) or CD123 (correspondig to pDCs). The purity of both DC subsets was 98% or more. For some imaging experiments, pDCs were isolated from elutriated monocytes from healthy blood donors with BDCA-4 magnetic beads and autoMACS sorting (Miltenyi) with a purity of over 90%.
Culture of pDCs and mDCs. Sorted peripheral blood pDCs and mDCs were cultured at a density of 1 Â 10 6 cells per ml in RPMI medium, 2 mM L-glutamine, penicillin-streptomycin and 10% (vol/vol) FCS. For the matrix protein-tetramer proliferation assay, both DC subsets were cultured in the presence of human serum. The pDCs were cultured in the presence of interleukin 3 (IL-3; 10 ng/ml; R&D Systems) as a survival factor. For DC activation, pDCs (in the absence of IL-3) and mDCs were cultured in the presence of live influenza virus A/PR/8/34 (40 hemagglutinin units/ml; Charles River Laboratories) or ultraviolet irradiation-inactivated influenza virus A/PR/ 8/34 (crosslinking for 20 min at 254 nm and a maximum setting; UVGL-25 crosslinker; UVP). In some experiments, pDCs and mDCs were pretreated for 20 min with brefeldin A (2.5 mg/ml), cyclohexamide (5 mg/ml), lactacystine (100 mM), primaquine (50 mM), cholorquine (50 mM) or z-FA-fmk (benzyloxycarbonyl-Phe-Ala-fluoromethylketone; all from Sigma) before further treatment. Influenza matrix protein tetramer proliferation assay. CD8 + T cells were isolated from HLA-A2 donors as described above and then were labeled with CFSE. Autologous pDCs and mDCs treated with IL-3 or influenza virus were added to CD8 + T cells at a ratio of 1:20. For some experiments, pDCs and mDCs were fixed for 10 min in Cyto-Chex (213355; Streck) and were washed three times in PBS before being cultured together with the CD8 + T cells. After 6 d, cells were collected and washed and then were stained with allophycocyanin-conjugated anti-CD8 (Becton Dickinson) and phycoerythrin-conjugated influenza matrix protein tetramer (T01011; Beckman Coulter). For exclusion of dead cells, recovered cells were resuspended in 7-amino-actinomycin D solution (20 mg/ml; A9400; Sigma) and were analyzed on a BD FACSAria. Data were analyzed with FlowJo software. For functionality analysis, matrix protein tetramer-positive CD8 + cells from influenza virus-treated pDCs were sorted and were cultured in presence of allogenic HLA-A2 + monocyte-derived DCs pulsed with influenza matrix protein peptide IMF 58-66. After 18 h, supernatants were collected and IFN-g was measured by Luminex assay.
Matrix protein tetramer-positive cell lines. HLA-A2 + peripheral blood mononuclear cells were cultivated in RPMI medium with 8% (vol/vol) human serum in presence of 1 mM IMF 58-66 peptide. IL-2 was added every 2 d. Cells positive for CD3, CD8 and matrix protein tetramer were sorted and were exposed to allogenic HLA-A2 + pDCs treated with IL-3 or influenza virus in presence or absence of inhibitors. IFN-g was measured by Luminex assay after 2 and 4 h of culture.
Statistics. P values were determined by the paired t-test with Prism 4.0 (GraphPad).
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